Hybrid scheme of eradication therapy of helicobacter pylori infection: systematization of literature data


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Reduced effectiveness of standard schemes of eradication therapy (ET) of Helicobacter pylori infection, correlating with an increase in antibiotic resistance of a microorganism, determines the feasibility of the development and a comprehensive evaluation of alternative variants of ET. The hybrid ET, proposed in 2011 by Chinese researchers and successfully tested in a number of countries in Asia, Europe and the Middle East, has attracted wide attention of the international gastroenterological community through a combination of efficacy and acceptable safety. This review systematizes literature data on the hybrid scheme of ET, including its efficacy, safety, tolerability, and its current place as a method of prevention and treatment of H. pylori-associated diseases.

Full Text

Restricted Access

About the authors

G. L Yurenev

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

D. N Andreev

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

Email: dna-mit8@mail.ru
PhD, Teaching Assistant at the Department of Propedeutics of Internal Diseases and Gastroenterology, Scientific Researcher at the Laboratory of Functional Methods of Examination in Gastroenterology

E. V Partsvaniya-Vinogradova

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

D. T Dicheva

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

References

  1. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М., 2016.
  2. Morgan D.R., Crowe S.E. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management/ edited by M. Feldman, L.S. Friedman, L.J. Brandt. 10th ed. 2015.
  3. Руководство по внутренней медицине / Под ред. ГП. Арутюнова, А.И. Мартынова, А.А. Спасского. М., 2015.
  4. Malfertheiner P., Megraud F., O'Morain C.A., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
  5. Sugano K., Tack J., Kuipers E.J., et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.
  6. Fallone C.A., Chiba N., van Zanten S.V., et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14
  7. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Тер. архив. 2014;3:94-9.
  8. Hsu P.I., Wu D.C., Wu J.Y., Graham D.Y. Modified sequential Helicobacter pylori therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011;16:139-45.
  9. Molina-Infante J., Gisbert J.P Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J. Gastroenterol. 2014; 20:10338-47.
  10. Graham D.Y., Lee Y.C., Wu M.S. Rational Helicobacter pylori therapy: Evidence-based medicine rather than medicine-based evidence. Clin. Gastroenterol. Hepatol. 2014;12:177-86. e3.
  11. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterol. Hepatol. 2011;8:79-88.
  12. Самсонов А.А. Антибиотики схем эрадикации Helicobacter pylori. Чем мы ограничены в выборе препаратов? Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2008;4:63-8.
  13. Самсонов А.А., Андреев Д.Н., Гречушников В.Б., Айвазова Р.А. Резистентность Helicobacter pylori к компонентам эрадикационной терапии и пути ее преодоления. Фарматека. 2015;2:26-30.
  14. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Мед. совет. 2013;10:11-5.
  15. Gisbert J.P., Calvet X., O'Connor J.P., Mégraud F., O'Morain C.A. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opin Pharmacother.2010;11:905-18.
  16. Vaira D., Zullo A., Hassan C., Fiorini G., Vakil N. Sequential therapy for Helicobacter pylori eradication:The time is now! Therap. Adv. Gastroenterol. 2009;2:317-22.
  17. Zullo A., De Francesco V., Hassan C., Morini S., Vaira D. The sequential therapy regimen for Helicobacter pylori eradication:A pooled-data analysis. Gut. 2007;56:1353-57.
  18. Song Z.Q., Liu J., Zhou L.Y. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin. Med. J. (Engl). 2016;129(8):992-99.
  19. Graham D.Y., Lu H., Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007;12:275-78.
  20. Metanat H.A, Valizadeh S.M., Fakheri H., Malekil., Taghvaei T., Hosseini V., et al. Comparison between 10- and 14-day hybrid regimens for Helicobacter pylorieradication: a randomized clinical trial. Helicobacter. 2015;20:299-304.
  21. Wu J.Y., Hsu P.l., Wu D.C., Graham D.Y., Wang W.M. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014;19:207-13.
  22. Cuadrado-Lavln A., Salcines-Caviedes J.R., Diaz-Perez A., Carrascosa M.F., Ochagavla M., Fernandez-Forcelledo J.L., et al. First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori:An open-label, randomized, multicentre clinical trial. J. Antimicrob. Chemother. 2015;70:2376-81.
  23. Heo J., Jeon S.W., Jung J.T., Kwon J.G., bee D.W., Kim H.S., et al. Concomitant and hybrid therapy for Helicobacter pylori infection:A randomized clinical trial. J. Gastroenterol. Hepatol. 2015;30:1361-66.
  24. Chen K.Y., Lin T.J., Lin C.L., Lee H.C., Wang C.K., Wu D.C. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. World J. Gastroenterol. 2015;21:10435-42.
  25. Hsu P.I., Wu D.C., Wu J.Y., Graham D.Y. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011;16:146-52.
  26. Sardarian H., Fakheri H., Hosseini V., Taghvaei T., Maleki I., Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: A prospective randomized trial. Helicobacter. 2013;18:129-34.
  27. Zullo A., Scaccianoce G., De Francesco V., Ruggiero V., D'Ambrosio P., Castorani L., et al. Concomitant, sequential, and hybrid therapy for H pylori eradication: A pilot study. Clin. Res. Hepatol. Gastroenterol. 2013;37:647-50.
  28. De Francesco V., Hassan C., Ridola L., Giorgio F., Ierardi E., Zullo A. Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication:A prospective randomized study. J. Med. Microbiol. 2014;63(Pt. 5):748-52.
  29. Oh D.H., Lee D.H., Kang K.K., Park Y.S., Shin C.M., Kim N., et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J. Gastroenterol. Hepatol. 2014;29:1171-76.
  30. Molina-Infante J., Romano M., Fernandez-Bermejo M., Federico A., Gravina A.G., Pozzati L., et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies